Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor

Journal of Cystic Fibrosis(2024)10.1016/j.jcf.2024.02.015Source: DataRank Database

Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor is a research paper published in Journal of Cystic Fibrosis (2024). On theSindex it has a DataRank of 0. It has been cited 12 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access12 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 3.39)OA: bronzeTopics (61)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Christopher E. Pope,Hillary S. Hayden ORCID,Carson J. Miller ORCID,Stephen J. Salipante ORCID,Steven M. Rowe ORCID

Live enrichment

PubMed:38448281 PMC:PMC11182717 OpenAlex:https://openalex.org/W4392501783

NHLBI NIH HHS

Grant: K24 HL141669

NIDDK NIH HHS

Grant: P30 DK072482

NIDDK NIH HHS

Grant: P30 DK089507

Seattle Children's Research Institute

National Institutes of Health

Cystic Fibrosis Foundation

FWCI

3.39

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

bronzeLicense: http://creativecommons.org/licenses/by-nc-nd/4.0/

journalhttps://www.cysticfibrosisjournal.com/article/S1569-1993(24)00029-8/pdf

publisherhttps://www.cysticfibrosisjournal.com/article/S1569-1993(24)00029-8/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1569199324000298?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1569199324000298?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jcf.2024.02.015

Fields of Study

Cystic Fibrosis Research AdvancesGut microbiota and healthLiver Disease and TransplantationAdolescentAdultFemaleHumansMaleYoung AdultAminophenolsBenzodioxolesChloride Channel AgonistsCystic FibrosisDrug CombinationsDysbiosisFecesGastrointestinal MicrobiomeIndolesLiver DiseasesPyrazolesPyridinesPyrrolesPyrrolidinesQuinolones

MeSH Terms

Gastrointestinal MicrobiomeAdolescentAdultAminophenolsCystic FibrosisDrug CombinationsFecesFemaleHumansIndolesLiver DiseasesMalePyrazolesPyridinesPyrrolesPyrrolidinesQuinolonesBenzodioxolesYoung AdultDysbiosisChloride Channel Agonists

Keywords

IvacaftorCystic fibrosisMedicineCystic fibrosis transmembrane conductance regulatorDysbiosisPathogenesisLiver diseaseDiseaseInflammationGastroenterologyInternal medicineImmunologyGut-liver AxisFecal MicrobiomeCystic Fibrosis Liver DiseaseElexacaftor/Tezacaftor/Ivacaftor

Sustainable Development Goals

SDG 0: Good health and well-being